dipyridamole has been researched along with Akinetic-Rigid Variant of Huntington Disease in 2 studies
Dipyridamole: A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752)
dipyridamole : A pyrimidopyrimidine that is 2,2',2'',2'''-(pyrimido[5,4-d]pyrimidine-2,6-diyldinitrilo)tetraethanol substituted by piperidin-1-yl groups at positions 4 and 8 respectively. A vasodilator agent, it inhibits the formation of blood clots.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Erythrocytes from patients with Huntington's disease showed no significant differences from erythrocytes of normal adults." | 1.26 | Lysophosphatidylcholine-induced lysis of erythrocytes in Duchenne and myotonic dystrophies and in Huntington's disease. ( Barr, AN; Danon, MJ; Lazowski, E; Omachi, A; Podolski, JL; Sarpel, G, 1982) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (50.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Guitart, X | 1 |
| Chern, Y | 1 |
| Ferré, S | 1 |
| Omachi, A | 1 |
| Sarpel, G | 1 |
| Podolski, JL | 1 |
| Barr, AN | 1 |
| Lazowski, E | 1 |
| Danon, MJ | 1 |
2 other studies available for dipyridamole and Akinetic-Rigid Variant of Huntington Disease
| Article | Year |
|---|---|
Targeting the equilibrative nucleoside transporter ENT1 in Huntington disease.
Topics: Age of Onset; Animals; Animals, Genetically Modified; Biomarkers; Brain; Carrier Proteins; Corpus St | 2017 |
Lysophosphatidylcholine-induced lysis of erythrocytes in Duchenne and myotonic dystrophies and in Huntington's disease.
Topics: Adult; Child; Dipyridamole; Dose-Response Relationship, Drug; Erythrocytes; Hemolysis; Humans; Hunti | 1982 |